Back to Results
First PageMeta Content
Didanosine / Hepatitis / Medicine / Pharmacology / Health / Hepatitis C and HIV co-infection / Emtricitabine/tenofovir/efavirenz / Bristol-Myers Squibb / Protease inhibitors / Hepatitis C


Bristol-Myers pulls U.S. marketing application for hepatitis C treatment Oct 7 (Reuters) - Bristol-Myers Squibb said it withdrew its U.S. marketing application for a drug combination to treat hepatitis C. The drugmaker w
Add to Reading List

Document Date: 2014-10-08 16:23:27

Open Document

File Size: 62,93 KB

Share Result on Facebook

City

PRINCETON / Bristol / /

Company

Bristol-Myers Squibb / Bristol-Myers Squibb Co. / /

Country

Japan / United States / /

Event

FDA Phase / /

IndustryTerm

treatment of HCV / investigational product / medicinal products / hepatitis C treatment / /

MedicalCondition

HCV infection / HIV / HCV genotype 3 / hepatitis C. The / hepatitis C / HCV / HCV genotype / /

MedicalTreatment

liver transplant / /

Organization

European Union / U.S. Food and Drug Administration / American Association for the Study of Liver Diseases / /

Product

ribavirin / NS5A / /

ProvinceOrState

New Jersey / /

Technology

genotype / /

SocialTag